The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticlesFull Access

Linking Primary Care Patients to Mental Health Care via Behavioral Health Social Workers: A Stepped-Wedge Study

Abstract

Objective:

Demand for systematic linkage of patients to behavioral health care has increased because of the widespread implementation of depression screening. This study assessed the impact of deploying behavioral health social workers (BHSWs) in primary care on behavioral health visits for depression or anxiety.

Methods:

This quasi-experimental, stepped-wedge study included adults with a primary care visit between 2016 and 2019 at Cleveland Clinic, a large integrated health system. BHSWs were deployed in 40 practices between 2017 and 2019. Patients were allocated to a control group (diagnosed before BHSW deployment) and an intervention group (diagnosed after deployment). Data were collected on behavioral health visits (i.e., to therapists and psychiatrists) within 30 days of the diagnosis. Multilevel logistic regression models identified associations between BHSW deployment period and behavioral health visit, adjusted for demographic variables and clustering within each group.

Results:

Of 68,659 persons with a diagnosis, 21% had a depression diagnosis, 49% an anxiety diagnosis, and 31% both diagnoses. In the period after BHSW deployment, the proportion of patients with depression who had a behavioral health visit increased by 10 percentage points, of patients with anxiety by 9 percentage points, and of patients with both disorders by 11 percentage points. The adjusted odds of having a behavioral health visit was higher in the postdeployment period for patients with depression (adjusted odds ratio [AOR]=4.35, 95% confidence interval [CI]=3.50–5.41), anxiety (AOR=4.27, 95% CI=3.57–5.11), and both (AOR= 3.26, 95% CI=2.77–3.84).

Conclusions:

Integration of BHSWs in primary care was associated with increased behavioral health visits.

HIGHLIGHTS

  • Health systems need a systematic approach to connect patients with a new diagnosis of depression or anxiety to behavioral health services.

  • This quasi-experimental, stepped-wedge study evaluated whether deploying behavioral health social workers (BHSWs) in primary care settings increased patients’ odds of receiving treatment within 30 days after diagnosis.

  • After BHSW deployment, the likelihood of having a visit with a therapist or psychiatrist increased more than threefold for patients with depression, anxiety, or both diagnoses.

  • Other health systems that have advanced electronic health records systems should consider integrating BHSWs in primary care to triage patients with newly diagnosed depression and anxiety and systematically link them to behavioral care.

The U.S. Preventive Services Task Force recommends that health care systems screen patients for depression to improve identification of this underdiagnosed and undertreated condition (1, 2). However, identifying depression does not ensure treatment and subsequent improvement in health outcomes (3). Health systems need a systematic approach to connect patients with a new diagnosis of depression to therapy (4, 5). Furthermore, systems built to link patients with depression to treatment may also benefit patients with other behavioral health conditions (e.g., anxiety).

Implementing systematic treatment for depression can be challenging because of inadequate funding for and access to behavioral health resources (6). In research settings, the collaborative care model has been shown to improve care outcomes (7). The original model, published more than 20 years ago, colocated behavioral health providers within the primary care practice (8). However, health systems that want to colocate primary and behavioral health providers face financial, training, and process barriers (9, 10). New strategies to link patients to behavioral health services have emerged. The University of Washington pilot tested a centralized remote care management program that employed clinicians to monitor patients’ progress via chart review and facilitate engagement when appropriate. Patients in the program were more likely to have a follow-up Patient Health Questionnaire (PHQ-9) score recorded and to have improved PHQ-9 scores (11). Another study found that using a smartphone application that allowed the health care team to send appointment reminders, monitor symptoms, and share educational material reduced follow-up time, compared with usual care (12). Solutions do not always require advanced technology. One novel approach is to employ licensed independent social workers, previously used to facilitate in-person collaborative care (13), to instead facilitate care across sites.

With the widespread implementation of electronic health records (EHRs), it is easier to share information (14). EHRs enable clinicians to collaborate even when physically distant (15). Given the increased demand for behavioral health care necessitated by depression screening, the need for primary care physicians and behavioral health specialists to collaborate is pressing. In 2016, Cleveland Clinic implemented systematic depression screening, which increased identification of patients with depression (16). To link these patients to appropriate resources, the health system deployed behavioral health social workers (BHSWs)—licensed independent social workers with specialized behavioral health training—in primary care practices. Although the impetus to deploy BHSWs was depression screening, patients with anxiety often have similar needs (17), and physicians could also refer them to BHSWs. The objective of this study was to identify the impact of BHSWs on use of behavioral health services and pharmacotherapy in the 30 days after a patient’s initial diagnosis with depression or anxiety.

Methods

This quasi-experimental, stepped-wedge study (18, 19) included adults who received a new diagnosis of depression or anxiety between January 2016 and December 2019. We included patients who had at least one primary care visit at a location that was supported by BHSWs by February 2019. Because we were interested only in patients with a new diagnosis, we excluded anyone who had a diagnosis of depression or anxiety in 2015 or received a prescription for an antianxiety or antidepressant medication in 2015. EHR data were collected through February 2020, enabling a 35-day follow-up period after a visit. The Cleveland Clinic Institutional Review Board approved this study.

BHSW Intervention

Over 15 months (October 2017–January 2019), 10 BHSWs were hired to support 40 primary care practices (i.e., the staff-led practices within our large, integrated health system). Each BHSW supported internal and family medicine physicians in person at the BHSW’s primary site and via telephone at satellite sites. On average, each BHSW supported 45 physicians. The BHSWs worked full-time in this role and did not have additional responsibilities. Funding for BHSWs was through Cleveland Clinic’s Medicine Institute, but the BHSWs were supervised by a manager in the Behavioral Health Department of the Neurological Institute of Cleveland Clinic.

As BHSWs were hired, they were assigned to their preferred location. Often, the BHSWs chose their site according to where they lived. Hence, the order of BHSW deployment was not predetermined. Once a BHSW had been assigned, physicians within that group of sites (called “group”) could refer patients to the BHSW through a telephone encounter. In May 2018, an order set was implemented within the EHR to allow physicians to more easily refer patients to the BHSW. After receiving a referral through the EHR—or, less often, via warm handoff—the BHSW called the patient. The expectation was that BHSWs connected with a patient within 7 days. The BHSW administered a depression screener (i.e., the PHQ-9), asked about substance use and anxiety, and took a psychiatric history. The BHSW spoke with the patient for up to three times, offered community resources, or referred the patient to a behavioral health provider (i.e., a licensed independent social worker, psychiatrist, or psychologist). The resources available at each site (i.e., psychiatrist onsite) varied, which necessitated different approaches by each BHSW.

Independent Variable

In the stepped-wedge design, each site’s group served as its own internal control (pre- vs. postdeployment). We assigned the 40 primary practices to seven groups on the basis of when a BHSW started supporting the group of sites. (A figure in an online supplement to this article shows the time line.) The preintervention period lasted between 21 and 36 months.

Patients were assigned to the control or intervention group on the basis of the date of their initial diagnosis (the index date) of depression or anxiety during the study period. Patients were assigned to the intervention group if their condition was diagnosed after the BHSW started at the site, and patients whose index date was before the BHSW started were assigned to the control group. We excluded patients whose first diagnosis occurred during the month that the BHSW began working.

Diagnoses were based on ICD-10 codes assigned on the day of the visit (see table in online supplement). Patients who received a diagnosis of anxiety and depression on the same day were classified as having both.

Dependent Variables

Behavioral health services.

We collected dates of in-person and telephone visits with therapists (i.e., licensed independent social workers or psychologists) and in-person visits with psychiatrists from the EHR. We collected information on both telephone and in-person visits because cognitive-behavioral therapy is similarly effective when delivered by either modality (20). We determined whether a visit occurred within 30 days of the index visit, as a measure of the timeliness of care. We also assessed whether a patient had at least three visits with a therapist or psychiatrist within 90 days of his or her index date. We did not include visits to the BHSW as an outcome.

Composite treatment outcome.

We categorized patients’ treatment within 30 days into three groups: no treatment, medication only, and behavioral health visit. Patients included in the behavioral health visit group had a visit with a therapist or psychiatrist and may or may not have been prescribed a medication.

Medications.

Although the BHSWs were tasked with linking patients to therapy, we examined their impact on pharmacotherapy because many patients with newly diagnosed depression or anxiety initiate treatment with a medication, especially if behavioral therapy is not readily available (2, 21). From the EHR, we identified all psychotropic medications prescribed within 30 days of the index visit.

Confounders.

We collected information from the EHR on age (in years), sex (male or female), race (Black, White, or other), marital status (married or domestic partner vs. other), and health insurance (private, Medicare, Medicaid, or other).

Analysis

We described the change in the percentage of patients who received behavioral health treatment before or after BHSW deployment, stratified by diagnosis group (depression, anxiety, or both). We used multilevel logistic regression models to identify the association between BHSW deployment and receipt of treatment. Separately, we modeled the adjusted probability of having a visit with a therapist, having a visit with a psychiatrist, having a behavioral health visit, and receiving a prescription for pharmacotherapy. The regression models were adjusted for age, sex, race, insurance, and marital status as fixed effects. Intervention status (pre- versus postdeployment) was also included as a fixed effect. The site’s group and time were both included as random effects in the model (22). To understand whether a change in visits was due to deployment of the BHSWs or some other secular change in the health system, we plotted the adjusted probability of each event across time for each group. All analyses were conducted with Stata 14.0.

Secondary analysis.

We used the same analytic approach as in the main analysis to determine whether patients had higher odds of having at least three visits within 90 days of a diagnosis after BHSW deployment.

Sensitivity analysis.

We were concerned that we might miss behavioral health visits to therapists outside our health system. Hence, in a sensitivity analysis, we restricted the population to individuals insured by our employee health plan (EHP), because such individuals have strong financial incentives to stay within Cleveland Clinic’s health system.

Results

The study population included 68,659 persons who had at least one primary care visit between 2016 and 2019 and a diagnosis of depression (N=14,237, 21%), anxiety (N=33,377, 49%), or both (N=21,045, 31%). Patients seen before BHSW deployments were on average slightly older (49 vs. 48 years, p<0.01) and more likely to be female (66% vs. 64%, p<0.01) and Black (12% vs. 10%, p<0.01), compared with patients seen after BHSW deployment (Table 1). On average, 4,179 patients were diagnosed as having anxiety or depression each quarter during the predeployment period versus 4,755 during the postdeployment period (p=0.08).

TABLE 1. Characteristics of primary care patients with a new diagnosis of depression, anxiety, or both, by whether their index diagnosis visit was before or after behavioral health social workers were deployed in primary care

Predeployment (N=38,022)Postdeployment (N=30,637)
CharacteristicN%N%p
Mean age in years48.647.5<.01
Female25,0656619,67964<.01
Race<.01
 White30,7228125,11782
 Black4,693123,09010
 Othera2,60772,4308
Insurance<.01
 Private24,6906520,49967
 Medicare7,572205,78719
 Medicaid4,820133,77612
 Other94035752
Married18,7824914,95549.13
Diagnosis group<.01
 Depression only8,274225,96319
 Anxiety only17,1824516,19553
 Both12,566338,47928

aIncluded in other: unavailable or unknown, 33%; multiracial or multicultural, 30%; declined, 17%; Asian, 14%; other, 5%; and American Indian or Alaska Native, 2%.

TABLE 1. Characteristics of primary care patients with a new diagnosis of depression, anxiety, or both, by whether their index diagnosis visit was before or after behavioral health social workers were deployed in primary care

Enlarge table

Behavioral Health Visits

Visits with a therapist increased from 2% in the predeployment period to 11% postdeployment for patients with depression (p<0.01) and from 2% to 10% (p<0.01) for patients with anxiety (Table 2). The adjusted odds of having a visit with a therapist increased in the postdeployment period for patients with depression (adjusted odds ratio [AOR]=4.97) and anxiety (AOR=5.00). The percentage of patients with a psychiatrist visit increased from 1% to 2% for patients with depression (p<0.01). In the regression model, the AOR for having a psychiatry visit was 1.82 for patients with depression and 1.58 for patients with anxiety (Table 2).

TABLE 2. Behavioral health treatment within 30 days of a diagnosis of depression, anxiety, or both among primary care patients with an index diagnosis visit before (pre) or after (post) behavioral health social worker deployment in primary care, and adjusted odds of treatment receipt

DepressionAnxietyDepression and anxiety
UnadjustedUnadjustedUnadjusted
Pre (N=8,274)Post (N=5,963)Pre (N=17,182)Post (N=16,195)Pre (N=12,566)Post (N=8,479)
TreatmentN%N%AORa95% CIN%N%AORa95% CIN%N%AORa95% CI
Medicationb4,363533,313561.00.92–1.099,303548,16850.80.76–.858,451675,69767.89.82–.94
Therapist visit1932659114.973.88–6.3736621,625105.004.09–6.1448941,151143.673.07–4.46
Psychiatrist visit116114521.821.37–2.44173123811.581.25–2.01251224231.481.20–1.83
Behavioral health visitc2623748134.353.50–5.4148031,761114.273.57–5.1163551,291153.262.77–3.84

aAOR, adjusted odds ratio. Reference groups: no prescription, no visit with a therapist, no psychiatrist visit, and no behavioral health visit. The models were adjusted for age, sex, race, insurance, and marital status as fixed effects. Intervention status (yes vs. no) was included as a fixed effect. The site’s group and time (in yearly quarters) were both included as random effects. df=12 for all adjusted models.

bPrescription for anxiety or depression medication.

cTherapist or psychiatrist visit.

TABLE 2. Behavioral health treatment within 30 days of a diagnosis of depression, anxiety, or both among primary care patients with an index diagnosis visit before (pre) or after (post) behavioral health social worker deployment in primary care, and adjusted odds of treatment receipt

Enlarge table

In the postdeployment period, the percentage of patients with at least one behavioral health visit increased by approximately 10 percentage points (p<0.01 for all comparisons) (Figure 1). For patients with depression only, the proportion of those with a visit increased from 4% predeployment to 14% postdeployment (p<0.01) and for patients with anxiety, from 3% to 12% (p<0.01). The likelihood of having any behavioral health visit (therapist or psychiatrist) was significantly higher in the postdeployment period for patients with depression (AOR=4.35) or anxiety (AOR=4.27) (Table 2).

FIGURE 1.

FIGURE 1. Outcomes within 30 days of diagnosis among primary care patients with new diagnoses of depression, anxiety, or both, before (pre) or after (post) behavioral health social workers were deployed in primary carea

aPatients who had a visit with a therapist or psychiatrist within 30 days of the index (diagnosis) visit were grouped in the behavioral health visit group regardless of whether they were also prescribed a medication. Depression-only group: predeployment, N=8,274 (N=3,774 had no treatment, N=4,167 were prescribed a medication, and N=333 had a behavioral health visit); postdeployment, N=5,963 (N=2,282 had no treatment, N=2,855 were prescribed a medication, and N=826 had a behavioral health visit). Anxiety-only group: predeployment, N=17,182 (N=7,592 had no treatment, N=9,001 were prescribed a medication, and N=589 had a behavioral health visit); postdeployment, N=16,195 (N=6,954 had no treatment, N=7,350 were prescribed a medication, and N=1,891 had a behavioral health visit). Depression and anxiety group: predeployment, N=12,566 (N=3,868 had no treatment, N=7,910 were prescribed a medication, and N=788 had a behavioral health visit); postdeployment, N=8,479 (N=2,304 had no treatment, N=4,741 were prescribed a medication, and N=1,434 had a behavioral health visit). Chi-square tests indicated a statistically significant difference (p<0.01) in treatment received within each group between the pre- and postdeployment periods.

Trends in Behavioral Health Care

Figure 2 shows the adjusted probability of having a visit with a therapist or a psychiatrist by group over time. In the BHSW postdeployment period, therapist visits clearly increased, and most groups’ adjusted probability of having a visit significantly increased after BHSW deployment (p<0.01). The exception was the group of sites that transitioned in the third quarter of 2018 (group 3), for which the likelihood of a therapist visit remained relatively flat for the entire study period. As Figure 2 also shows, the increase in the adjusted probability of having a visit with a psychiatrist was overall slight and substantially varied across groups.

FIGURE 2.

FIGURE 2. Therapist and psychiatrist visits within 30 days of a new depression or anxiety diagnosis among primary care patients, by year and groupa

aWe classified the 40 primary practices into seven groups on the basis of when a behavioral health social worker started supporting each site group. Group 1 transitioned in October 2017; group 2, in February 2018; group 3, in April 2018; group 4, in May 2018; group 5, in August 2018; group 6, in November 2018; and group 7, in January 2019.

Medications

The adjusted odds of receiving a medication among patients with depression indicated no changes after BHSW deployment (Table 2). For patients with anxiety, medication prescriptions overall decreased by 4 percentage points in the postdeployment period. This change was driven by a decrease in prescribing benzodiazepines (predeployment, 19%, N=3,207; postdeployment, 13%, N=2,089; p<0.01). Patients with anxiety had significantly reduced odds of receiving a prescription in the postdeployment period (AOR=0.80). Similarly, patients with both anxiety and depression had lower odds of receiving a prescription in the regression model (AOR=0.89).

Secondary Analysis

We also calculated the percentage of patients who received at least three behavioral health visits within 90 days. Before BHSW deployment, 1% (N=504 of 38,022) of patients had at least three visits within 90 days of the index visit. After deployment, 3% of patients (N=1,000 of 30,637) had at least three visits (p<0.01). The likelihood of having at least three behavioral health visits within 90 days was significantly higher in the postdeployment period (AOR=2.56, 95% confidence interval=2.13–3.07).

Sensitivity Analysis

When we restricted our analysis to individuals with EHP insurance (N=6,785), our results were similar to the results of the main analysis (Table 3). Among patients with depression in this group, 17% received a behavioral health visit in the 30 days after diagnosis, versus 6% before BHSW deployment. For patients with depression, the likelihood of receiving any behavioral health treatment was higher after the deployment (AOR=3.84).

TABLE 3. Behavioral health treatment within 30 days of a diagnosis of depression, anxiety, or both among primary care patients with employee health insurance plan and an index diagnosis visit before (pre) or after (post) behavioral health social worker deployment in primary care, and adjusted odds of receipt of a behavioral health visit

Depression only (N=1,062)Anxiety only (N=3,652)Depression and anxiety (N=2,071)
PrePostPrePostPrePost
TreatmentN%N%AORa95% CIN%N%AORa95% CIN%N%AORa95% CI
Medicationb34658286611,00755975548087064170
Behavioral health visitc34680173.842.46–5.98845238133.522.59–4.81878159172.992.20–4.07

aAOR, adjusted odds ratio. Reference group: patients who did not have a behavioral health visit. The models were adjusted for age, sex, race, insurance, and marital status as fixed effects. Intervention status (yes vs. no) was included as a fixed effect. The site’s group and time (in yearly quarters) were both included as random effects. df=9 for the adjusted models.

bPrescription for anxiety or depression medication.

cTherapist or psychiatrist visit.

TABLE 3. Behavioral health treatment within 30 days of a diagnosis of depression, anxiety, or both among primary care patients with employee health insurance plan and an index diagnosis visit before (pre) or after (post) behavioral health social worker deployment in primary care, and adjusted odds of receipt of a behavioral health visit

Enlarge table

Discussion

We found that connections to behavioral health care increased substantially after the deployment of BHSWs in primary care. The odds of having at least one visit with a behavioral health specialist in the 30 days after diagnosis increased more than threefold postdeployment for patients with depression, anxiety, or both. This increase was primarily due to visits with therapists. Of note, the absolute increase in behavioral health visits was approximately 10 percentage points, and the absolute increase in psychiatry visits was smaller (1 percentage point). Findings from our study support the notion that BHSWs can connect patients to therapists and psychiatrists even when they are based in separate locations.

Although patients with depression can be treated with pharmacotherapy, linking patients to behavioral therapy is important because patients often prefer it to pharmacotherapy (23). In our study, 13% of patients with a diagnosis of depression attended a behavioral health visit. In comparison, 4% of patients with depression attended a behavioral health visit after the implementation of a quality improvement project at 16 primary care practices (21). The project included training sessions and a Web-based application to screen, monitor, and guide treatment decisions (21). Patients with mild depression should be initially offered therapy plus symptom monitoring, and patients with moderate depression should be offered therapy, pharmacotherapy, or both (24). For patients who require both, there is no order effect on eventual outcomes (25), and initial treatment with behavioral therapy, which has no known adverse effects, may be therefore preferable.

Incidentally, we found that prescriptions for benzodiazepines decreased after BHSW deployment. This decrease may be linked to benzodiazepines’ association with opioid overdose deaths (26) and physicians’ changing prescribing habits (27) in response to the public’s perception that these habits were partly responsible for the opioid epidemic (28). Benzodiazepines are safe when prescribed for short periods, but dependence can develop after 4 weeks for half of benzodiazepines users (29). For patients with a new diagnosis of anxiety, physicians may have been reluctant to withhold pharmacotherapy if they did not have an alternative. Given that behavioral health visits increased after BHSW deployment, their availability to link patients to treatment may have encouraged physicians not to prescribe medications.

One of our study’s strengths was the inclusion of both depression and anxiety. Both disorders are common concerns (30) and frequently co-occur (31). A study of primary care patients in Germany found that patients with both depression and anxiety were more likely to receive behavioral health treatment (OR=5.16), compared with patients with either disease (32). Similarly, we found that the proportion of patients who received behavioral health treatment was larger among those who had both diagnoses than among those with only one. We also found that a slightly higher percentage of patients with only depression were linked to treatment, compared with patients with only anxiety. Ideally, primary care patients with behavioral health needs, such as anxiety, will also benefit from systematic supports linking patients to treatment. Thus, quality of care can be improved for patients beyond those with a specific disease for which a quality measure has been incorporated into value-based payment programs.

To meet quality measures within pay-for-quality programs, practices are increasingly screening their patients for depression and are identifying new cases of this disorder (33). After diagnosis, patients with depression should be linked to care to prevent unnecessary emergency department and hospital visits (34), which are key drivers of cost for accountable care organizations (ACOs) (35). A study found that incentivizing behavioral health care through ACO payments did not meaningfully improve receipt of care, in part because of limited provider capacity (36). The findings of our study suggest that health systems and ACOs should consider employing BHSWs to increase short-term capacity and link patients to appropriate care. Virtual visits (including via telephone) can increase capacity, because a clinician is not restricted to a specific location or usual office hours. Instead, a behavioral health specialist can meet with patients anywhere and may choose to offer evening or weekend hours. Increased care access outside routine business hours may be important, given that patients with financial instability are more likely to miss behavioral health appointments (37). Further, a meta-analysis found that interventions led by a remote therapist are as effective as in-person ones (38), and clinicians and patients’ ability to use remote interventions has been expanded during the COVID-19 pandemic (39).

This observational study had several limitations. First, sites were not randomly assigned to receive the intervention. Unmeasured bias may have been present in the order and timing of the BHSW deployment. Importantly, the order in which each group transitioned was independent of the group’s eagerness to work with a BHSW. Second, depression and anxiety are relapsing and remitting disorders. Patients who received a diagnosis earlier than 2015 might have been included in the data set if they did not receive a diagnosis of, or medication for, depression or anxiety in 2015. However, our approach has been used previously (2). Further, patients who experience a relapse of depression that has been in remission for ≥1 year should be treated similarly to those who have received a new diagnosis. Third, it is possible that the introduction of the BHSWs led to a change in physicians’ pattern of identifying and diagnosing depression or anxiety. Fourth, patients might have sought mental health care outside our integrated health system. Our sensitivity analyses of patients likely to stay within our health system found a similar increase in the adjusted odds of treatment after the deployment of the BHSW, suggesting that our findings are likely reliable and that more patients received treatment in the first month after diagnosis. Finally, we know anecdotally that the BHSWs varied in their approach to linking patients to care on the basis of patients’ needs and location-specific resources. Although these differences in approach decreased the consistency of the intervention across practice sites, these varied approaches likely increased the external generalizability of our study.

Conclusions

The results of our large, retrospective, stepped-wedge study indicate that deploying BHSWs in primary care practices increased linkages to behavioral health care for patients with depression and anxiety. Other health systems that have advanced EHR systems should consider introducing social workers trained in behavioral health to triage patients receiving new diagnoses of depression, anxiety, or both and systematically link them to appropriate care.

Center for Value-Based Care Research (Pfoh, Rothberg), Cleveland Clinic Community Care (Hohman, Vakharia), and Department of Psychology (Alcorn), Cleveland Clinic, Cleveland.
Send correspondence to Dr. Pfoh ().

This study was made possible in part by funding from the Clinical and Translational Science Collaborative of Cleveland by grant KL2TR002547 from the National Center for Advancing Translational Sciences, which supports Dr. Pfoh.

The authors report no financial relationships with commercial interests.

References

1 Siu AL, Bibbins-Domingo K, Grossman DC, et al.: Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA 2016; 315:380–387Crossref, MedlineGoogle Scholar

2 Waitzfelder B, Stewart C, Coleman KJ, et al.: Treatment initiation for new episodes of depression in primary care settings. J Gen Intern Med 2018; 33:1283–1291Crossref, MedlineGoogle Scholar

3 Thombs BD, Ziegelstein RC, Roseman M, et al.: There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Med 2014; 12:13Crossref, MedlineGoogle Scholar

4 Yang M, Loeb DF, Sprowell AJ, et al.: Design and implementation of a depression registry for primary care. Am J Med Qual 2019; 34:59–66Crossref, MedlineGoogle Scholar

5 Thompson H, Faig W, Gupta N, et al.: Collaborative care for depression of adults and adolescents: measuring the effectiveness of screening and treatment uptake. Psychiatr Serv 2019; 70:604–607LinkGoogle Scholar

6 Deneke DE, Schultz H, Fluent TE: Screening for depression in the primary care population. Prim Care 2014; 41:399–420Crossref, MedlineGoogle Scholar

7 Unützer J, Katon W, Callahan CM, et al.: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002; 288:2836–2845Crossref, MedlineGoogle Scholar

8 Archer J, Bower P, Gilbody S, et al.: Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev 2012; 10:CD006525MedlineGoogle Scholar

9 Solberg LI, Crain AL, Jaeckels N, et al.: The DIAMOND initiative: implementing collaborative care for depression in 75 primary care clinics. Implement Sci 2013; 8:135Crossref, MedlineGoogle Scholar

10 Whitebird RR, Solberg LI, Margolis KL, et al.: Barriers to improving primary care of depression: perspectives of medical group leaders. Qual Health Res 2013; 23:805–814Crossref, MedlineGoogle Scholar

11 Chang D, Carlo AD, Khor S, et al.: Transforming population-based depression care: a quality improvement initiative using remote, centralized care management. J Gen Intern Med 2021; 36:333–340Crossref, MedlineGoogle Scholar

12 Carleton KE, Patel UB, Stein D, et al.: Enhancing the scalability of the collaborative care model for depression using mobile technology. Transl Behav Med 2020; 10:573–579Crossref, MedlineGoogle Scholar

13 Carlo AD, Corage Baden A, McCarty RL, et al.: Early health system experiences with collaborative care (CoCM) billing codes: a qualitative study of leadership and support staff. J Gen Intern Med 2019; 34:2150–2158Crossref, MedlineGoogle Scholar

14 Adler-Milstein J, Holmgren AJ, Kralovec P, et al.: Electronic health record adoption in US hospitals: the emergence of a digital “advanced use” divide. J Am Med Inform Assoc 2017; 24:1142–1148Crossref, MedlineGoogle Scholar

15 Cifuentes M, Davis M, Fernald D, et al.: Electronic health record challenges, workarounds, and solutions observed in practices integrating behavioral health and primary care. J Am Board Fam Med 2015; 28(suppl 1):S63–S72Crossref, MedlineGoogle Scholar

16 Pfoh ER, Janmey I, Anand A, et al.: The impact of systematic depression screening in primary care on depression identification and treatment in a large health care system: a cohort study. J Gen Intern Med 2020; 35:3141–3147Crossref, MedlineGoogle Scholar

17 Löwe B, Spitzer RL, Williams JBW, et al.: Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008; 30:191–199Crossref, MedlineGoogle Scholar

18 Fok CCT, Henry D, Allen J: Research designs for intervention research with small samples: II. stepped wedge and interrupted time-series designs. Prev Sci 2015; 16:967–977Crossref, MedlineGoogle Scholar

19 Handley MA, Schillinger D, Shiboski S: Quasi-experimental designs in practice-based research settings: design and implementation considerations. J Am Board Fam Med 2011; 24:589–596Crossref, MedlineGoogle Scholar

20 Cuijpers P, Noma H, Karyotaki E, et al.: Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. JAMA Psychiatry. 2019; 76:700–707Crossref, MedlineGoogle Scholar

21 Jha MK, Grannemann BD, Trombello JM, et al.: A structured approach to detecting and treating depression in primary care: VitalSign6 project. Ann Fam Med 2019; 17:326–335Crossref, MedlineGoogle Scholar

22 Thompson JA, Fielding KL, Davey C, et al.: Bias and inference from misspecified mixed-effect models in stepped wedge trial analysis. Stat Med 2017; 36:3670–3682Crossref, MedlineGoogle Scholar

23 McHugh RK, Whitton SW, Peckham AD, et al.: Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry 2013; 74:595–602Crossref, MedlineGoogle Scholar

24 Park LT, Zarate CA: Depression in the primary care setting. N Engl J Med 2019; 380:559–568Crossref, MedlineGoogle Scholar

25 Dunlop BW, LoParo D, Kinkead B, et al.: Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry 2019; 176:275–286LinkGoogle Scholar

26 Benzodiazepines and Opioids. Bethesda, MD, National Institute on Drug Abuse, 2021. https://www.drugabuse.gov/drug-topics/opioids/benzodiazepines-opioidsGoogle Scholar

27 Zhu W, Chernew ME, Sherry TB, et al.: Initial opioid prescriptions among US commercially insured patients, 2012–2017. N Engl J Med 2019; 380:1043–1052Crossref, MedlineGoogle Scholar

28 Blendon RJ, Benson JM: The public and the opioid-abuse epidemic. N Engl J Med 2018; 378:407–411Crossref, MedlineGoogle Scholar

29 Soyka M: Treatment of benzodiazepine dependence. N Engl J Med 2017; 376:1147–1157Crossref, MedlineGoogle Scholar

30 Carroll AJ, Jaffe AE, Stanton K, et al.: Program evaluation of an integrated behavioral health clinic in an outpatient women’s health clinic: challenges and considerations. J Clin Psychol Med Settings 2020; 27:207–216Crossref, MedlineGoogle Scholar

31 Kircanski K, LeMoult J, Ordaz S, et al.: Investigating the nature of co-occurring depression and anxiety: comparing diagnostic and dimensional research approaches. J Affect Disord 2017; 216:123–135Crossref, MedlineGoogle Scholar

32 Hüsing P, Löwe B, Piontek K, et al.: Somatoform disorder in primary care: the influence of co-morbidity with anxiety and depression on health care utilization. J Eval Clin Pract 2018; 24:892–900Crossref, MedlineGoogle Scholar

33 Samples H, Stuart EA, Saloner B, et al.: The role of screening in depression diagnosis and treatment in a representative sample of US primary care visits. J Gen Intern Med 2020; 35:12–20Crossref, MedlineGoogle Scholar

34 Schmidt EM, Behar S, Barrera A, et al.: Potentially preventable medical hospitalizations and emergency department visits by the behavioral health population. J Behav Health Serv Res 2018; 45:370–388Crossref, MedlineGoogle Scholar

35 McWilliams JM, Hatfield LA, Landon BE, et al.: Medicare spending after 3 years of the Medicare shared savings program. N Engl J Med 2018; 379:1139–1149Crossref, MedlineGoogle Scholar

36 Counts NZ, Wrenn G, Muhlestein D: Accountable care organizations’ performance in depression: lessons for value-based payment and behavioral health. J Gen Intern Med 2019; 34:2898–2900Crossref, MedlineGoogle Scholar

37 Song AA, Oslin DW, Wolk CB: Characteristics of patients who attended behavioral health services after primary care referral with referral management support. Psychiatr Serv 2021; 72:1455–1459LinkGoogle Scholar

38 Linde K, Sigterman K, Kriston L, et al.: Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med 2015; 13:56–68Crossref, MedlineGoogle Scholar

39 Wosik J, Fudim M, Cameron B, et al.: Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc 2020; 27:957–962Crossref, MedlineGoogle Scholar